CHROMEDX CORP.
CONDENSED UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(PREPARED BY MANAGEMENT)
FOR THE THREE MONTH AND SIX MONTH PERIODS ENDED MARCH 31, 2016 AND 2015

INDEX

CHROMEDX CORP.
MANAGEMENT'S RESPONSIBILITY FOR FINANCIAL REPORTING
MARCH 31, 2016

The accompanying condensed unaudited interim consolidated financial statements of ChroMedX Corp. (the "Company") were prepared by management in accordance with International Financial Reporting Standards. Management acknowledges responsibility for the preparation and presentation of the financial statements, including responsibility for significant accounting judgments and estimates and the choice of accounting principles and methods that are appropriate to the Company's circumstances.

Management has established systems of internal control over the financial reporting process, which are designed to provide reasonable assurance that relevant and reliable financial information is produced.

The Board of Directors is responsible for ensuring that management fulfills its financial reporting responsibilities and for reviewing and approving the financial statements together with other financial information. The Audit Committee, on behalf of the Board of Directors, meets with management to review the internal controls over the financial reporting process, the financial statements together with other financial information of the Company, and the auditor's report. The Audit Committee reports its findings to the Board of Directors for its consideration in approving the financial statements for issuance to the shareholders. Management recognizes its responsibility for conducting the Company's affairs in compliance with established financial standards, and applicable laws and regulations, and for maintaining proper standards of conduct for its activities.

Notice of no auditor review of interim financial statements:

Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if an auditor has not performed a review of the interim financial statements they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying condensed unaudited interim consolidated financial statements of the Company have been prepared by, and are the responsibility of, the Company's management.

CHROMEDX CORP.
CONDENSED INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT
(Unaudited - in Canadian dollars)

		March 31, 2016		September 30, 2015
ASSETS				
Current				
Cash and cash equivalents	$	133,841	$	101,071
Amounts receivable		250,000		250,000
Prepaid expenses		2,400		127,400
HST receivable		36,701		80,682
		422,942		559,153
Reclamation bonds (Note 4)		70,025		69,901
Patents (Note 3)		2,724,575		2,857,343
	$	3,217,542	$	3,486,397
LIABILITIES				
Current				
Accounts payable and accrued liabilities	$	45,744	$	152,830
Due to related parties (Note 6)		500		9,605
		46,244		162,435
Provision for well abandonment costs (Note 4)		28,854		28,854
		75,098		191,289
SHAREHOLDERS' EQUITY (DEFICIENCY)				
Capital stock (Note 5(a))		6,384,102		6,077,065
Warrant reserve (Note 5(c))		625,450		477,437
Contributed surplus		541,876		485,750
Deficit		(4,408,984)		(3,745,144)
		3,142,444		3,295,108
	$	3,217,542	$	3,486,397

NATURE OF OPERATIONS AND GOING CONCERN, (Note 1)

Approved on behalf of the board:

"Wayne Maddever" President and Director
"Gerard Edwards" Director

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

CHROMEDX CORP.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE THREE MONTH AND SIX MONTH PERIODS ENDED MARCH 31, 2016 and 2015

(Unaudited - in Canadian dollars)

	Three Months		Six Months	
	2016	2015	**2016**	2015
Expenses				
Management fees (Note 6)	**$ 34,500**	$ 30,000	**$ 58,000**	$ 66,000
Consulting fees	**149,631**	195,024	**306,772**	514,490
Office, general and administrative	**45,539**	26,002	**83,302**	61,282
Professional fees	**16,785**	58,237	**26,872**	71,607
Patent amortization expense (Note 3)	**66,384**	85,497	**132,768**	163,022
Share- based compensation (Note 5(b))	**30,198**	62,715	**56,126**	235,211
Net loss and comprehensive loss for the period	**$ 343,037**	457,475	**$ 663,840**	$ 1,111,612
(Loss) per share				
Basic and fully diluted (Note 9)	**$ 0.00**	$ (0.01)	**$ (0.01)**	$ (0.03)
Weighted average number of common shares outstanding, basic and diluted	**57,061,230**	$ 44,878,817	**54,997,164**	40,395,755

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

CHROMEDX CORP.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
FOR THE THREE MONTH AND SIX MONTH PERIODS ENDED MARCH 31, 2016 and 2015
(Unaudited - in Canadian dollars)

	Capital Stock					
	Number of shares	Amount	Warrants reserve	Contributed surplus	Deficit	Total
Balance, October 1, 2014	35,912,693	$ 3,068,036	$ 173,720	$ 197,765	$ (1,653,548)	$ 1,785,973
Share issue on exercise of options	200,000	20,000	-	-	-	20,000
Share issue on exercise of warrant	1,287,500	209,125	-	-	-	209,125
Share issue on exercise of options - Patents	5,474,452	1,751,825	-	-	-	1,751,825
Fair value of options exercised	-	23,147	-	(23,147)	-	-
Fair value of warrants exercised	-	9,029	(9,029)	-	-	-
Share based compensation	-	-	-	235,211	-	235,211
Net loss for the period	-	-	-	-	(1,111,612)	(1,111,612)
Balance, March 31, 2015	42,874,645	$ 5,081,162	$ 164,691	$ 409,829	$ (2,765,160)	$ 2,890,522
Shares issued for cash, net of issuance costs	9,149,452	1,136,512	2,920	-	-	1,139,432
Share issue on exercise of options	500,000	50,000	-	-	-	50,000
Share issue on exercise of warrant	409,000	61,350	-	-	-	61,350
Fair value of options exercised	-	57,867	-	(57,867)	-	-
Fair value of warrants exercised and expired	-	14,689	(14,689)	-	-	-
Fair value of warrants	-	(324,515)	324,515	-	-	-
Share based compensation	-	-	-	133,788	-	133,788
Net loss for the period	-	-	-	-	(979,984)	(979,984)
Balance, September 30, 2015	52,933,097	$ 6,077,065	$ 477,437	$ 485,750	$ (3,745,144)	$ 3,295,108
Shares issued for cash, net of issuance costs (Note 5(a)(i))	1,850,000	342,000	-	-	-	342,000
Share issue for cash on exercise of warrants (Note 5(c))	787,000	113,050	-	-	-	113,050
Fair value on warrants (Note 5(c))	-	(148,013)	148,013	-	-	-
Share- based compensation (Note 5(b))	-	-	-	56,126	-	56,126
Net loss for the period	-	-	-	-	(663,840)	(663,840)
Balance, March 31, 2016	55,570,097	$ 6,384,102	$ 625,450	$ 541,876	$ (4,408,984)	$ 3,142,444

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

CHROMEDX CORP.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTH AND SIX MONTH PERIODS ENDED MARCH 31, 2016 and 2015
(Unaudited - in Canadian dollars)

	Three Months		Six Months	
	2016	2015	**2016**	2015
Cash flows from operating activities				
Net loss for the period	**$ (343,037)**	$ (457,475)	**$ (663,840)**	$ (1,111,612)
Adjustments not effecting cash:				
Patent amortization	**66,384**	85,497	**132,768**	163,022
Share-based compensation	**30,198**	62,715	**56,126**	235,211
Changes in non-cash working capital				
Amounts receivable	**22,302**	-	**-**	315
HST receivable	**12,830**	(9,087)	**43,981**	(10,279)
Prepaid expense	**62,500**	(8,957)	**125,000**	66,161
Accounts payable and accrued liabilities	**(65,628)**	123,008	**(107,087)**	63,533
Cash flows used in operating activities	**(214,451)**	(204,299)	**(413,052)**	(593,649)
Cash flows from investing activities				
Increase in reclamation bonds	**-**	(260)	**(123)**	(308)
Repayment (advances) of amounts due from related party	**(7,500)**	(3,365)	**(9,105)**	(13,365)
Cash flows used in investing activities	**(7,500)**	(3,625)	**(9,228)**	(13,673)
Cash flows from financing activities				
Issuance of common shares	**113,050**	-	**455,050**	229,125
Loan and advances from related party	**-**	49,000	**-**	49,000
Cash flows provided by financing activities	**113,050**	49,000	**455,050**	278,125
Net increase (decrease) in cash and cash equivalents	**(108,901)**	(158,924)	**32,770**	(329,197)
Cash and cash equivalents, beginning of period	**242,742**	152,958	**101,071**	323,231
Cash and cash equivalents, end of period	**$ 133,841**	$ (5,966)	**$ 133,841**	$ (5,966)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

1. NATURE OF OPERATIONS AND GOING CONCERN

ChroMedX Corp. ("the Company") (formerly Monarch Energy Limited") was incorporated in British Columbia and is engaged in the business of research, development and manufacturing of in vitro diagnostics and point-of-care technologies. The principal business address of the Company is 65 Queen Street West Suite 520, Toronto, Ontario, M5H 2M5.

The current market conditions and volatility increase the uncertainty of the Company's ability to continue as a going concern given the need to both manage expenditures and to raise additional funds. The Company is experiencing, and has experienced, negative operating cash flows and has working capital of $376,698 as at March 31, 2016 (September 30, 2015 - $396,718). The Company will continue to search for new or alternate sources of financing in order to continue development of its products but anticipates that the current market conditions may impact the ability to source such funds. These material uncertainties cast significant doubt on the Company's ability to continue as a going concern.

There can be no assurance that the Company will be able to continue to raise funds in which case the Company may be unable to meet its obligations. Should the Company be unable to realize on its assets and discharge its liabilities in the normal course of business, the net realizable value of its assets may be materially less than the amounts recorded on the condensed interim consolidated statement of financial position.

On June 30, 2014, the Company entered into a share exchange agreement with ChroMedX Ltd. ("ChroMedX") pursuant to which the Company has acquired from the ChroMedX shareholders all of the issued and outstanding shares of ChroMedX in exchange for an equal number of common shares in the capital of the Company (the "Acquisition"). ChroMedX will be the registered holder of certain patents and patents pending in the biomedical technology field. Upon completion of the Acquisition, ChroMedX became a wholly-owned subsidiary of the Company, and Monarch Energy Limited changed its name to ChroMedX Corp. The Acquisition was accounted for as a reverse acquisition (refer to note 4).

2. BASIS OF PRESENTATION

Statement of Compliance

The condensed interim unaudited consolidated financial statements have been prepared in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS 34"), as issued by the International Accounting Standards Board ("IASB") and therefore, do not contain all disclosures required by International Financial Report Standards ("IFRS") for annual financial statements.

The policies applied in these condensed interim unaudited consolidated financial statements are consistent with the policies disclosed in Notes 2 of the audited annual financial statements for the year ended September 30, 2015, prior to the year end change.

The condensed interim unaudited financial statements were authorized for issue by the Board of Directors on May 25, 2016.

Future Accounting Pronouncements

Standard issued but not yet effective up to the date of issuance of these financial statements is listed below. The Company intends to adopt this standard when it becomes effective.

IFRS 10 Consolidated Financial Statements, IFRS 12 Disclosure of Interests in Other Entities and IAS 28 Investments in Associates and Joint Ventures were amended to clarify the application of the requirement for investment entities to measure subsidiaries at fair value instead of consolidating them. The amendment is effective for annual periods beginning on or after January 1, 2016. Earlier application is permitted.

(Unaudited - in Canadian dollars)

IFRS 9, Financial Instruments, ("IFRS 9") was issued by the IASB in July 2014 in final form and will replace IAS 39, Financial Instruments: Recognition and Measurement ("IAS 39"). IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple rules in IAS 39. The approach in IFRS 9 is based on how an entity manages its financial instruments in the context of its business model and the contractual cash flow characteristics of the financial assets. Most of the requirements in IAS 39 for classification and measurement of financial liabilities were carried forward unchanged to IFRS 9. The new standard also requires a single impairment method to be used, replacing the multiple impairment methods in IAS 39. IFRS 9 is effective for annual periods beginning on or after January 1, 2018.

IFRS 16, Leases ("IFRS 16") will bring most leases on-balance sheet for lessees under a single model, eliminating the distinction between operating and finance leases. Lessor accounting however remains largely unchanged and the distinction between operating and finance leases is retained. Under IFRS 16 a lessee recognizes a right-of-use asset and a lease liability. The right-of-use asset is treated similarly to other non-financial assets and depreciated accordingly and the liability accrues interest. This will typically produce a front-loaded expense profile (whereas operating leases under IAS 17, Leases ("IAS 17") would typically have had straight-line expenses) as an assumed linear depreciation of the right-of-use asset and the decreasing interest on the liability will lead to an overall decrease of expense over the reporting period. IFRS 16 supersedes IAS 17 and related interpretations and is effective for periods beginning on or after 1 January 2019, with earlier adoption permitted if IFRS 15, Revenue from Contracts with Customers has also been applied.

Principles of Consolidation

These condensed interim consolidated consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, ChroMedX Ltd. All significant intercompany balances and transactions have been eliminated on consolidation.

3. PATENTS

The following is a summary of patents as at March 31, 2016:

Balance, December 31, 2013	$	-
Additions		1,515,300
Amortization		(75,765)
Balance, September 30, 2014	$	1,439,535
Additions		1,751,825
Amortization		(334,017)
Balance, September 31, 2015	$	2,857,343
Amortization		(132,768)
Balance, March 31, 2016	$	2,724,575

This asset relates to patents and a patent option which was granted by InvidX Corp ("InvidX") to the Company to acquire all rights, title and interest in and to the Patents, exercisable on or before 2 years following the date of the Option Agreement dated June 16 2014. In consideration of the option granted, the Company issued 15,000,000 common shares in the capital of the Company as of June 16 2014. The Company may exercise the option during the 2 year period for a purchase of $1,500,000, such purchase price to be satisfied either by a cash payment or through the issuance of common shares of the Company at a minimum price of 20% discount to the 10-day volume weight average trading price of the Company's common shares immediately preceding the exercise of the option.

On December 9, 2014, the Company exercised the option and in consideration, issued 5,474,452 common shares to InvidX Corp. InvidX is controlled by an officer of the Company.

(Unaudited - in Canadian dollars)

4. PROVISION FOR WELL ABANDONMENT COSTS

The Company holds reclamation bonds with the Alberta Energy Regulator as required by section 1.100(2) of the Oil and Gas Conservation Regulations and Directive 006: License Liability Rating Program and License Transfer Process. The reclamation bonds are held for the purposes of the future well abandonment, related to the business of the Company prior to the reverse takeover transaction.

A provision to close and abandon a gas well using a discount rate of 5%. Management expects to abandon the well within 10 years. The face value of the costs is $47,000.

5. CAPITAL STOCK

(a) **Common shares**

Authorized

The authorized capital stock of the Company consists of an unlimited number of common shares.

(i) In November 2015, the Company completed a private placement of 1,850,000 units at a price of $0.20 per unit for aggregate proceeds of $370,000. Each unit consist of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of $0.30 per a common share for a period of 24 months from the date of issuance. In connection with this financing, the Company paid cash commissions of $28,000 and issued 140,000 broker warrants where each broker warrant entitles the holder to acquire one additional common share at a price of $0.30 for a period of 24 months from the date of issuance.

(b) **Stock option plan and share-based compensation**

The Company has a stock option plan under which it is authorized to grant options to directors, employees and consultants enabling them to acquire up to 10% of the issued and outstanding common shares of the Company. Under the plan, the exercise price of each option equals the market price, minimum price, or a discounted price of the Company's shares as calculated on the date of grant. The options can be granted for a maximum term of 10 years.

The following table summarizes information concerning the Company's stock options outstanding as at March 31, 2016:

	Number of Options	Black-Scholes Value	Weighted Average Exercise Price
Outstanding and exercisable - September 30, 2012 and September 30, 2013	5,000,000	$ -	$ 0.10
Cancelled	(5,000,000)	-	0.10
Granted	2,950,000	341,418	0.10
Outstanding as at September 30, 2014	2,950,000	$ 341,418	$ 0.10
Granted	1,150,000	225,718	0.26
Exercised	(700,000)	(81,014)	0.10
Outstanding at at September 30, 2015	3,400,000	$ 486,122	$ 0.15
Granted	620,000	55,754	0.20
Outstanding as at March 31, 2016	4,020,000	541,876	$ 0.16

(Unaudited - in Canadian dollars)

The following common share purchase options are outstanding at March 31, 2016:

Date of Grant	Number of options outstanding	Exercise Price	Weighted Average remaining life (years)	Expiry Date	Number of options exercisable
July 10, 2014	2,250,000	$ 0.10	3.22	July 10, 2019	2,250,000
October 9, 2014	600,000	$ 0.18	1.44	October 7, 2017	600,000
December 10, 2014	550,000	$ 0.345	3.58	December 10, 2019	550,000
December 7, 2015	620,000	$ 0.20	4.61	December 7, 2020	248,000
	4,020,000	$ 0.16			3,648,000

In the condensed interim consolidated statement of operations, the Company recorded stock-based compensation expense of $56,126 for the period ended March 31, 2016 (March 31, 2015 - $235,211).

(c) **Warrants**

The following table summarizes warrants that have been issued, exercised or have expired during the period ended March 31, 2016:

	Number of Warrants	**Black-Scholes Value**	**Weighted Average Exercise Price**
Balance, beginning	-	$ -	$ -
Issued	12,920,000	173,720	0.22
Balance, September 30, 2014	12,920,000	$ 173,720	$ 0.22
Exercised	(1,696,500)	(11,019)	0.16
Issued	9,183,452	327,435	0.20
Expired	(1,485,000)	(12,699)	0.15
Balance, September 30, 2015	18,921,952	$ 477,437	$ 0.22
Exercised	(787,000)	(9,562)	0.15
Expired	(379,000)	(138)	0.15
Issued	1,990,000	157,713	0.30
Balance, March 31, 2016	19,745,952	$ 625,450	$ 0.23

At March 31, 2016, the following warrants were outstanding. The warrants entitle the holders to purchase the stated number of common shares at the exercise price on or before the expiry date:

Warrants	**Exercise Price**	**Fair Value**	**Expiry date**
2,427,500	$ 0.25	$ 21,756	December 31, 2016
1,770,000	$ 0.25	$ 26,641	December 31, 2016
4,375,000	$ 0.25	$ 91,905	December 31, 2016
9,183,452	$ 0.20	$ 327,435	January 11, 2017
1,990,000	$ 0.30	$ 157,713	October 14, 2017
19,745,952		$ 625,450	

(Unaudited - in Canadian dollars)

6. RELATED PARTY TRANSACTIONS

Related parties and related party transactions impacting the accompanying financial statements are summarized below and include transactions with the following individuals or entities:

As at March 31, 2016, amounts due to related parties consist of $500 (September 30, 2015 - $9,605) to companies controlled by officers and directors of the Company. In addition, the Company paid $30,000 for management fees and $1,500 consulting fees to officers and directors (March 31, 2015 - $30,000 and $1,000).

Key management personnel:

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of executive and non executive members of the Company's Board of Directors and corporate officers.

Remuneration attributed to key management personnel can be summarized as follows:

	March 31, 2016	March 31, 2015
Share-based compensation (note 5(b))	$ 12,060	$ 53,868
Short-term benefits*	$ 31,500	$ 31,500

*includes base salaries pursuant to contractual employment, or consultancy arrangements. These have been recorded in consulting fees and management fees.

7. FINANCIAL RISK FACTORS

The Company manages its exposure to a number of different financial risks arising from its operations as well as its use of financial instruments including market risks (commodity prices, foreign currency exchange rate and interest rate), credit risk and liquidity risk through its risk management strategy. The objective of the strategy is to support the delivery of the Company's financial targets while protecting its future financial security and flexibility.

Financial risks are primarily managed and monitored through operating and financing activities and, if required, through the use of derivative financial instruments. The financial risks are evaluated regularly with due consideration to changes in the key economic indicators and up-to-date market information.

The Company's financial instruments consist of cash and cash equivalents, amounts receivable, due from related party, reclamation bonds, accounts payable and accrued liabilities, and amounts due to related parties. The fair value of the Company's receivables, due from related party, accounts payable and accrued liabilities, and amounts due to related parties approximate their carrying value, due to their short-term maturities or ability of prompt liquidation. The Company's cash and cash equivalents are recorded at fair value, under the fair value hierarchy, based on level one quoted prices in active markets for identical assets or liabilities. The Company's other financial instrument, being reclamation bonds, are measured at amortized cost.

The Company is exposed in varying degrees to a variety of financial instrument related risks.

Market Risk

Market risk is the risk or uncertainty arising from possible market price movements and their impact on the future performance of the business. These market risks are evaluated by monitoring changes in key economic indicators and market information on an on-going basis.

a) Interest Rate Risk

The Company has cash balances, and is not at a significant risk to fluctuating interest rates. The Company's current policy is to invest excess cash in investment-grade short-term deposit certificates issued by its banking institutions. The Company periodically monitors the investments it makes and is satisfied with the credit ratings of its banks. As of March 31, 2016, the Company did not have any investments in investment-grade short-term deposit certificates.

b) Foreign currency risk

As at March 31, 2016, the Company's expenditures are predominantly in Canadian dollars, and any future equity raised is expected to be predominantly in Canadian dollars and therefore is not at a significant risk to fluctuating exchange risks.

Liquidity Risk

Liquidity risk encompasses the risk that a company cannot meet its financial obligations in full. The Company's main sources of liquidity is derived from its common stock issuances. These funds are primarily used to finance working capital, operating expenses, capital expenditures, and acquisitions.

The Company manages its liquidity risk by regularly monitoring its cash flows from operating activities and holding adequate amounts of cash and cash equivalents.

As at March 31, 2016, the Company held cash of $133,841 to settle current liabilities of $46,244. All of the Company's non-provision liabilities are due with the next fiscal year.

Credit Risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents. The Company has reduced its credit risk by investing its cash equivalents with a Canadian chartered bank.

8. CAPITAL MANAGEMENT

The Company defines capital management in the manner it manages its capital stock. As at March 31, 2016 the Company's capital stock was $6,384,102.

There were no changes in the Company's approach to capital management during the period ended March 31, 2016 and the Company is not subject to any externally imposed capital requirements.

The Company's objectives when managing capital are:

a) To safeguard the Company's financial capacity and liquidity for future earnings in order to continue to provide an appropriate return to shareholders and other stakeholders;

b) To maintain a flexible capital structure which optimizes the cost of capital at an acceptable risk; and

c) To enable the Company to maximize growth by meeting its capital expenditure budget, to expand its budget to accelerate projects, and to take advantage of acquisition opportunities.

The Company's capital structure includes components of shareholders' equity.

The Company regularly monitors and reviews the amount of capital in proportion to risk and future development and exploration opportunities. The Company manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may issue new debt or equity or similar instruments, reduce debt levels from, or make adjustments to, its capital expenditure program.

9. BASIC AND DILUTED LOSS PER SHARE

Basic loss per share has been calculated by dividing the net loss per the financial statements by the weighted average number of shares outstanding during the year. The fully diluted loss per share would be calculated using a common share balance increased by the number of common shares that could be issued on the exercise of outstanding warrants and options of the Company. As the Company is in a loss position for the period ended March 31, 2016, this would be anti-dilutive.